Innovative BioMedical Devices
ABN 35 088 221 078

bioMD Limited
Level 11, 225 St Georges Terrace
Perth, Western Australia 6000
PO Box 7209, Cloisters Square
Western Australia 6850

Telephone (08) 9262 6777
Facsimile (08) 9322 3433
ABN 35 088 221 078
www.biomd.com.au

ANNOUNCEMENT TO THE AUSTRALIAN STOCK EXCHANGE

1 page 15 December 2009

NAMSA BIOCOMPATIBIITY TESTING

PERTH Australia: bioMD Limited (ASX:BOD) announces that biocompatibility testing of the ADAPT® biomaterial has commenced at the NAMSA testing facility in the United States.

NAMSA is the world's leading medical device contract research organisation specialising in the safety and evaluation of medical devices.

The testing will give the necessary biocompatibility certification for its biomaterial patch products and will be used as an integral part of the regulatory submissions to the TGA/FDA/CE late in 2010.

The testing of the ADAPT biomaterial involves a series of tests, 21 in total, that cover areas such as sensitisation, cytotoxicity, bacterial, activation assays and systemic toxicity. These tests are scheduled to be completed by August 2010.

During this period of testing the company will be assembling the technical dossier for the ADAPT biomaterial, including the clinical evidence from all our small animal studies completed over the past years and our recently completed human clinical trial on heart deformities in South Africa. The Company will also complete its quality assurance program and be preparing a conformity assessment for the biomaterial that will form the basis of the regulatory submissions.

About bioMD Limited

bioMD (ASX: BOD) is an Australian company commercialising innovative tissue engineering technology for use in cardiothoracic and abdominal surgery. The ADAPT technology offers significant improvements to current tissue processing technologies in terms of immunogenicity and tissue durability. Its lead product, CardioCel, continues to be evaluated in a Phase II human trial in South Africa for various cardiac repair procedures. bioMD is currently maximising shareholder value via pursuit of corporate partnerships, successful completion of clinical milestones and rapid commercialisation strategies.

About the ADAPT® Tissue Engineering Process

The ADAPT Tissue Engineered Process (TEP), developed by Celxcel Pty Ltd, a subsidiary of bioMD, produces a bioprosthetic scaffold (extracellular matrix) made from animal tissue. Depending on the site of implantation, the patient's own cells will migrate into the matrix and stimulate site specific controlled remodelling. At the same time, new blood vessels are formed in the matrix and they deliver appropriate cells that lead to a functional tissue repair. The implanted extracellular matrix is gradually remodelled and replaced by the body's own new tissue structures.